A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Trial Profile

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2017

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 01 May 2017 Results were published in a Foamix media release.
    • 01 May 2017 Status changed from active, no longer recruiting to completed, according to a Foamix media release.
    • 27 Mar 2017 Primary endpoint has not been met. (Severity of acne vulgaris assessed by Investigator Global Assessment (IGA)), according to a Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top